1. Camilla Mattiuzzi,Giuseppe Lippi.Cancerstatistics: a comparison between World Health Organization (WHO) and Global Burden of Disease (GBD).Eur J Public Health.2019 Nov 25. pii: ckz216. doi: 10.1093/eurpub/ckz216.
2.Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017.CA: a cancer journal for clinicians.2017;67:7–30.
3. Shannon N Westin,Russell R Broaddus.Personalized therapy in endometrial cancer: Challenges and opportunities.Cancer Biol Ther. Jan 1, 2012; 13(1): 1–13.
4. Odagiri T., Watari H., Hosaka M., et al. Multivariate survival analysis of the patients with recurrent endometrial cancer.Journal of Gynecologic Oncology.2011;22(1):3–8.
5. Mankoo BS, Skuntz S, Harrigan I, et al. The concerted action of Meox homeobox genes is required upstream of genetic pathways essential for the formation, patterning and differentiation of somites.Development.2003;130:4655–4664.
6.Thiaville MM, Stoeck A, Chen L, et al. Identification of PBX1 target genes in cancer cells by global mapping of PBX1 binding sites.PloS one.2012;7:e36054.
7.Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.The Journal of Clinical Investigation.2011;121:2750–2767.
8.Lichao Sun,Hebao Yuan,Joseph Burnett,et al.MEOX1 Promotes Tumor Progression and Predicts Poor Prognosis in Human Non-Small-Cell Lung Cancer.Int J Med Sci. 2019; 16(1): 68–74.
9.Sun L, Burnett J, Gasparyan M, et al. Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer.Oncotarget.2016;7:51408–51422.
10.Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet. 2005;366:491-505.
12.Brown AK, Madom L, Moore R, et al. The prognostic significance of lower uterine segment involvement in surgically staged endometrial cancer patients with negative nodes. Gynecol Oncol. 2007;105:55-58.
13.Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015.CA: a cancer journal for clinicians.2016;66:115–132.
14.Yanokura M, Banno K, Iida M, et al. MicroRNAS in endometrial cancer: Recent advances and potential clinical applications.EXCLI J.2015;14(5):190–98.
15.Winterhoff B, Konecny GE. Targeting fibroblast growth factor pathways in endometrial cancer.Curr Probl Cancer.2016;41(1):37–47.
16.Westin SN, Broaddus RR. Personalized therapy in endometrial cancer: challenges and opportunities. Cancer Biol Ther. 2012;13:1-13.
17.Mohamed Jawahir Y, Faqeih E, Alsiddiky A, et al. Mutations in MEOX1, Encoding Mesenchyme Homeobox 1, Cause Klippel-Feil Anomaly. American Journal of Human Genetics. 2013;92:157–161.
18.Zhu ZY,Wang XL,Li DP.Silencing of MEOX1 Gene Inhibits Proliferation and Promotes Apoptosis of LNCaP Cells in Prostate Cancer.Cancer BiotherRadiopharm.2019 ;34(2):91-102.
19.Kun Dong, Xia Guo,Weiping Chen,et al. Mesenchyme homeobox 1 mediates transforming growth factor-β (TGF-β)–induced smooth muscle cell differentiation from mouse mesenchymal progenitors. J Biol Chem. 2018; 293(22): 8712–8719.
20.Isabel Rodrigo, Paola Bovolenta,Baljinder S. Mankoo, et al. Meox Homeodomain Proteins Are Required for Bapx1 Expression in the Sclerotome and Activate Its Transcription by Direct Binding to Its Promoter. Mol Cell Biol. 2004 Apr; 24(7): 2757–2766.
21.Yukiharu Todo,Sho Takeshita,Kazuhira Okamoto,et al. Implications of para-aortic lymph node metastasis in patients with endometrial cancer without pelvic lymph node metastasis. J Gynecol Oncol. 2017 ; 28(5): e59.